Epilepsy-Drug Pipeline Analysis and Market Forecasts to 2015

Oct. 8, 2010 - PRLog -- "Epilepsy-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global epilepsy market. The report identifies the key trends shaping and driving the global epilepsy market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global epilepsy sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:I37
-Annualized global epilepsy market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.  
-Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action includes Voltage-gated ion channels (¦Á2-¦Ä subunit of the voltage-gated Ca++ channel; the ¦Á subunits of voltage-gated Na+ channels; K+ channels); Enhancement of GABA-mediated transmissions, Acetylcholine agonists, NMDA targetters, Benzodiazepines.
-Analysis of the current and future market competition in the global epilepsy market. Key market players covered are Pfizer, UCB Pharma, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Abbott Laboratories, Sanofi-Aventis SA, and Cephalon.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with epilepsy.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global epilepsy market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global epilepsy market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global epilepsy market landscape? -Identify, understand and capitalize.



Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Epilepsy Market: Market Characterization 6
2.1 Overview 6
2.2 Epilepsy Market Size 6
2.3 Epilepsy Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Epilepsy Market 7
2.4.1 Drivers for the Epilepsy Market 8
2.4.2 Barriers for the Epilepsy Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 10
3 Epilepsy Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Epilepsy Market 12
3.3.1 Lyrica (Pregabalin) 12
3.3.2 Gabitril (Tiagabine Hcl) 13
3.3.3 Banzel (Rufinamide) 14
3.3.4 Vimpat (Lacosamide) 15
3.3.5 Felbatol (Felbamate) 16
3.3.6 Sabril (Vigabatrin) 18
3.4 Key Takeaway 20
4 Epilepsy Market: Pipeline Assessment 21
4.1 Overview 21
4.2 Strategic Pipeline Assessment 21
4.2.1 Technology Trends Analytic Framework 21
4.3 Epilepsy Therapeutics-Promising Drugs under Clinical Development 22
4.4 Molecule Profile for Promising Drugs under Clinical Development 23
4.4.1 Stedesa (Eslicarbazepine Acetate) 23
4.4.2 Comfyde (Carisbamate) 24
4.4.3 Retigabine 25
4.4.4 Brivaracetam 26
4.4.5 Ganaxolone 26
4.5 Epilepsy Therapeutics Market-Clinical Pipeline by Mechanism of Action 27
4.6 Epilepsy Pipeline-Pipeline by Clinical Phases of Development 28
4.6.1 Epilepsy Therapeutics-Regulatory and Phase III Clinical Pipeline 28
4.6.2 Epilepsy Therapeutics-Phase II Clinical Pipeline 30
4.6.3 Epilepsy Therapeutics-Phase I Clinical Pipeline 31
4.6.4 Epilepsy Therapeutics-Preclinical Pipeline 31
4.7 Discontinued/Suspended Drugs for Epilepsy 31
4.8 Key Takeaway 31
5 Epilepsy Market: Implications for Future Market Competition 33
6 Epilepsy Market: Future Players in the Epilepsy Market 34
6.1 Introduction 34
6.2 GlaxoSmithKline plc 34
6.2.1 Overview 34
6.2.2 CNS Portfolio 35
6.2.3 Epilepsy Portfolio 36
6.3 UCB Pharmaceuticals 38
6.3.1 Overview 38
6.3.2 CNS Portfolio 38
6.3.3 Epilepsy Product Portfolio 39
6.4 Johnson & Johnson 39
6.4.1 Overview 39
6.4.2 CNS Portfolio 40
6.4.3 Epilepsy Product Portfolio 40
6.5 Pfizer Inc. 41
6.5.1 Overview 41
6.5.2 CNS Portfolio 42
6.5.3 Epilepsy Product Portfolio 43
6.6 Sepracor Inc 44
6.6.1 Overview 44
6.6.2 CNS Portfolio 44
6.7 Supernus Pharmaceuticals Inc 45
6.7.1 Overview 45
6.7.2 CNS Portfolio 46
6.7.3 Epilepsy Product Portfolio 46
7 Epilepsy Market: Appendix 47
7.1 Market Definitions 47
7.2 Abbreviations 47
7.3 Research Methodology 48
7.3.1 Coverage 48
7.3.2 Secondary Research 49
7.3.3 Forecasting 49
7.3.4 Primary Research 51
7.3.5 Expert Panel validation 52
7.4 Contact Us 52
7.5 Disclaimer 52
7.6 Sources 52

List of Tables
1.1 List of Tables
Table 1: Global Cystic Fibrosis Therapeutics Market, Revenue ($m), 2000-2008 7
Table 2: Global Cystic Fibrosis Therapeutics Market, Revenue ($m), 2009-2015 7
Table 2: Major Marketed Products Comparison in the Epilepsy Market, 2009 19
Table 3: Epilepsy Therapeutics-Most Promising Drugs Under Clinical Development, 2009 22
Table 4: Epilepsy Therapeutics-Phase III Clinical Pipeline, 2009 28
Table 5: Epilepsy Therapeutics-Phase II Clinical Pipeline, 2009 30
Table 6: Epilepsy Therapeutics-Phase I Clinical Pipeline, 2009 31
Table 7: Epilepsy Therapeutics-Preclinical Pipeline, 2009 31
Table 8: GlaxoSmithKline-CNS Marketed Products, 2009 35
Table 9: GlaxoSmithKline-CNS Pipeline Products, 2009 36
Table 10: UCB Pharma-CNS Marketed Products, 2009 38
Table 11: UCB Pharma-CNS Pipeline Products, 2009 38
Table 12: Johnson & Johnson-CNS Marketed Products, 2009 40
Table 13: Johnson & Johnson-CNS Pipeline Products, 2009 40
Table 14: Pfizer-CNS Marketed Products, 2009 42
Table 15: Pfizer-CNS Pipeline Products, 2009 42
Table 16: Sepracor Inc -CNS Marketed Products, 2009 44
Table 17: Sepracor Inc-CNS Pipeline Products, 2009 44
Table 18: Supernus Pharmaceuticals-CNS Pipeline Products, 2009 46

List of Figures
1.2 List of Figures
Figure 1: Global Epilepsy Market Revenue ($m) 2000-2015 7
Figure 2: Opportunity and Unmet Need, 2009 9
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Epilepsy, 2009 11
Figure 4: Technology Trends Analytic Framework of the Epilepsy Pipeline, 2009 21
Figure 5: Technology Trends Analytic Framework of the Epilepsy Pipeline-Description, 2009 22
Figure 6: Epilepsy Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2009 28
Figure 7: Epilepsy Pipeline by Phase of Clinical Development, 2009 28
Figure 8: Implications for Future Market Competition in the Epilepsy Market, 2009 33
Figure 9: Epilepsy Therapeutics Market-Clinical Pipeline by Company, 2009 34
Figure 10: GlobalData Methodology 48
Figure 11: GlobalData Market Forecasting Model 51

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.